Clinical Features and Risk Factors of Adrenal Insufficiency in Patients With Cancer Admitted to the Hospitalist-Managed Medical Unit
© 2022 The Korean Academy of Medical Sciences..
BACKGROUND: The symptoms of adrenal insufficiency (AI) overlap with the common effects of advanced cancer and chemotherapy. Considering that AI may negatively affect the overall prognosis of cancer patients if not diagnosed in a timely manner, we analyzed the incidence, risk factors, and predictive methods of AI in cancer patients.
METHODS: We retrospectively analyzed the medical records of 184 adult patients with malignancy who underwent a rapid adrenocorticotrophic hormone stimulation test in the medical hospitalist units of a tertiary hospital. Their baseline characteristics and clinical features were evaluated, and the risk factors for AI were identified using logistic regression analysis.
RESULTS: Of the study patients, 65 (35%) were diagnosed with AI, in whom general weakness (63%) was the most common symptom. Multivariate logistic regression showed that eosinophilia (adjusted odds ratio [aOR], 4.28; 95% confidence interval [CI], 1.10-16.63; P = 0.036), history of steroid use (aOR, 2.37; 95% CI, 1.10-5.15; P = 0.028), and history of megestrol acetate use (aOR, 2.71; 95% CI, 1.38-5.33; P = 0.004) were associated with AI. Baseline cortisol levels of 6.2 μg/dL and 12.85 μg/dL showed a specificity of 95.0% and 95.4% for AI diagnosis, respectively.
CONCLUSION: AI was found in about one-third of patients with cancer who showed general symptoms that may be easily masked by cancer or chemotherapy, suggesting that clinical suspicion of AI is important while treating cancer patients. History of corticosteroids or megestrol acetate were risk factors for AI and eosinophilia was a pre-test predictor of AI. Baseline cortisol level appears to be a useful adjunct marker for AI.
| Errataetall: |
CommentIn: J Korean Med Sci. 2022 Jul 18;37(28):e232. - PMID 35851865 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of Korean medical science - 37(2022), 28 vom: 18. Juli, Seite e222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kwon, Min Kwan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Insufficiency |
|---|
| Anmerkungen: |
Date Completed 20.07.2022 Date Revised 02.08.2022 published: Electronic CommentIn: J Korean Med Sci. 2022 Jul 18;37(28):e232. - PMID 35851865 Citation Status MEDLINE |
|---|
| doi: |
10.3346/jkms.2022.37.e222 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343720329 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343720329 | ||
| 003 | DE-627 | ||
| 005 | 20231226021116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3346/jkms.2022.37.e222 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343720329 | ||
| 035 | |a (NLM)35851863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kwon, Min Kwan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Features and Risk Factors of Adrenal Insufficiency in Patients With Cancer Admitted to the Hospitalist-Managed Medical Unit |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2022 | ||
| 500 | |a Date Revised 02.08.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: J Korean Med Sci. 2022 Jul 18;37(28):e232. - PMID 35851865 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Korean Academy of Medical Sciences. | ||
| 520 | |a BACKGROUND: The symptoms of adrenal insufficiency (AI) overlap with the common effects of advanced cancer and chemotherapy. Considering that AI may negatively affect the overall prognosis of cancer patients if not diagnosed in a timely manner, we analyzed the incidence, risk factors, and predictive methods of AI in cancer patients | ||
| 520 | |a METHODS: We retrospectively analyzed the medical records of 184 adult patients with malignancy who underwent a rapid adrenocorticotrophic hormone stimulation test in the medical hospitalist units of a tertiary hospital. Their baseline characteristics and clinical features were evaluated, and the risk factors for AI were identified using logistic regression analysis | ||
| 520 | |a RESULTS: Of the study patients, 65 (35%) were diagnosed with AI, in whom general weakness (63%) was the most common symptom. Multivariate logistic regression showed that eosinophilia (adjusted odds ratio [aOR], 4.28; 95% confidence interval [CI], 1.10-16.63; P = 0.036), history of steroid use (aOR, 2.37; 95% CI, 1.10-5.15; P = 0.028), and history of megestrol acetate use (aOR, 2.71; 95% CI, 1.38-5.33; P = 0.004) were associated with AI. Baseline cortisol levels of 6.2 μg/dL and 12.85 μg/dL showed a specificity of 95.0% and 95.4% for AI diagnosis, respectively | ||
| 520 | |a CONCLUSION: AI was found in about one-third of patients with cancer who showed general symptoms that may be easily masked by cancer or chemotherapy, suggesting that clinical suspicion of AI is important while treating cancer patients. History of corticosteroids or megestrol acetate were risk factors for AI and eosinophilia was a pre-test predictor of AI. Baseline cortisol level appears to be a useful adjunct marker for AI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adrenal Insufficiency | |
| 650 | 4 | |a Eosinophilia | |
| 650 | 4 | |a Hospitalists | |
| 650 | 4 | |a Megestrol Acetate | |
| 650 | 4 | |a Neoplasms | |
| 650 | 7 | |a Megestrol Acetate |2 NLM | |
| 650 | 7 | |a TJ2M0FR8ES |2 NLM | |
| 650 | 7 | |a Hydrocortisone |2 NLM | |
| 650 | 7 | |a WI4X0X7BPJ |2 NLM | |
| 700 | 1 | |a Kim, Junhwan |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Jonghwa |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Chang-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyeonjeong |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Hye-Seon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Mingee |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Seungha |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Keun Hoi |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Young Hak |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jakyung |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Sujeung |e verfasserin |4 aut | |
| 700 | 1 | |a Son, Hyo-Ju |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Korean medical science |d 1995 |g 37(2022), 28 vom: 18. Juli, Seite e222 |w (DE-627)NLM012649317 |x 1598-6357 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2022 |g number:28 |g day:18 |g month:07 |g pages:e222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3346/jkms.2022.37.e222 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2022 |e 28 |b 18 |c 07 |h e222 | ||